Cadrenal Therapeutics, Inc. (CVKD)
NASDAQ: CVKD · Real-Time Price · USD
4.700
-0.200 (-4.08%)
At close: Apr 2, 2026, 4:00 PM EDT
4.780
+0.080 (1.70%)
After-hours: Apr 2, 2026, 6:14 PM EDT
Cadrenal Therapeutics Employees
Cadrenal Therapeutics had 4 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
4
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$3,309,341
Market Cap
11.78M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 4 | 0 | - |
| Dec 31, 2023 | 4 | 1 | 33.33% |
| Dec 31, 2022 | 3 | - | - |
| Sep 30, 2022 | 1 | - | - |
| Jun 30, 2022 | 1 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| BioAtla | 61 |
| CytoMed Therapeutics | 43 |
| BioLineRx | 24 |
| Moleculin Biotech | 17 |
| Soligenix | 16 |
| NewcelX | 15 |
| BioVie | 13 |
| Cellectar Biosciences | 11 |
CVKD News
- 2 days ago - Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting - GlobeNewsWire
- 21 days ago - Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes - GlobeNewsWire
- 4 weeks ago - Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion - GlobeNewsWire
- 5 weeks ago - Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement - GlobeNewsWire
- 2 months ago - Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX Inhibitor - GlobeNewsWire
- 3 months ago - Cadrenal's Pipeline Looks Less Like a Microcap and More Like an Emergency Response System - Accesswire
- 3 months ago - Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On - Accesswire
- 3 months ago - Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026 - GlobeNewsWire